GRF.MC · MCE · Healthcare
Grifols, S.A.
Also onConsensus Drift
Implied value per share
EUR 10.10
Market price
EUR 9.54
Implied upside
+5.8%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (EUR). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | EUR 8.1bn | EUR 8.7bn | EUR 9.3bn | EUR 10.0bn | EUR 10.8bn | +7.5% |
| EBIT | EUR 1.1bn | EUR 1.2bn | EUR 1.3bn | EUR 1.4bn | EUR 1.5bn | +7.5% |
| NOPAT | EUR 843.3m | EUR 906.2m | EUR 973.8m | EUR 1.0bn | EUR 1.1bn | +7.5% |
| Add depreciation & amortisation | EUR 517.4m | EUR 556.0m | EUR 597.4m | EUR 642.0m | EUR 689.8m | +7.5% |
| Less capital expenditure | EUR -443.9m | EUR -477.0m | EUR -512.6m | EUR -550.8m | EUR -591.8m | +7.5% |
| Less increase in working capital | EUR -55.7m | EUR -59.9m | EUR -64.4m | EUR -69.2m | EUR -74.3m | +7.5% |
| Free cashflow to firm | EUR 861.1m | EUR 925.3m | EUR 994.3m | EUR 1.1bn | EUR 1.1bn | +7.5% |
| Discount factor | 0.9653 | 0.8995 | 0.8381 | 0.7810 | 0.7277 | - |
| Present value | EUR 831.2m | EUR 832.2m | EUR 833.3m | EUR 834.4m | EUR 835.4m | +0.1% |
| Present Value Of The Forecast | EUR 4.2bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 4.20% | USD assumption - no free live source available for this market (assumption) |
| Equity risk premium | 6.50% | Market assumption |
| Beta | 1.127 | Reported 1.190, pulled toward 1.0 (Blume) |
| Cost of equity | 11.53% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.85% | Interest expense / average total debt |
| Market capitalisation | EUR 6.5bn | 40.4% of capital |
| Total debt | EUR 9.6bn | 59.6% of capital, book value as a proxy |
| Tax rate | 23.8% | Effective, capped at statutory |
| WACC | 7.32% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
73% of EV
- Forecast FCFF, final year
- EUR 1.1bn
- Capex at depreciation, working capital in reinvestment
- EUR 1.1bn
- Less reinvestment at g/ROIC (34.2% of NOPAT)
- EUR -384.0m
- Capitalised
- EUR 740.3m
- ROIC (WACC floor)
- 7.3%
- Terminal value, undiscounted
- EUR 15.7bn
- Terminal value, discounted
- EUR 11.5bn
- Enterprise value
- EUR 15.6bn
- Less net debt
- EUR 8.7bn
- Equity value
- EUR 6.9bn
Exit at 9.0x EBITDA
77% of EV
- Terminal value, undiscounted
- EUR 19.4bn
- Terminal value, discounted
- EUR 14.1bn
- Enterprise value
- EUR 18.3bn
- Less net debt
- EUR 8.7bn
- Equity value
- EUR 9.5bn
Spread between methods: 32%.
Sensitivity
Value per share (EUR) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 5.32% | 20.21 | 21.24 | 22.62 | 24.54 | 27.45 |
| 6.32% | 13.65 | 13.80 | 13.97 | 14.16 | 14.38 |
| 7.32% | 9.93 | 10.02 | 10.10 | 10.18 | 10.26 |
| 8.32% | 7.19 | 7.26 | 7.33 | 7.40 | 7.47 |
| 9.32% | 5.05 | 5.10 | 5.16 | 5.22 | 5.28 |
Outlined: this model. Green text: above today's price of 9.54. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 7.5% | 6.8% | -0.6pp |
| EBIT margin | 13.7% | 13.3% | -0.3pp |
| Discount rate | 7.3% | 7.5% | +0.2pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.